Photo of Dr Rakesh Popat

Dr Rakesh Popat

Telephone:

Email:

Location:

  • University College Hospital Grafton Way Building
  • University College Hospital Macmillan Cancer Centre

GMC/GDC number:

4432920

Professional background

Rakesh Popat is a consultant haematologist at University College Hospital with a specialist interest in multiple myeloma. He leads the myeloma clinical trials program and is the cancer programme lead for the National Institute for Health Research (NIHR) University College London Hospitals Clinical Research Facility. Dr. Popat completed his PhD in novel treatments for myeloma and was awarded a fellowship to attend the Dana-Farber Cancer Institute in Boston, MA, USA.

Dr. Popat is the Chair of the UK Myeloma Research Alliance (UKMRA), the science lead of the executive board of the UK Myeloma Society (UKMS) and the Young Board of the European Myeloma Network (EMN). In addition, he is a member of the International Myeloma Working Group (IMWG) where he is an active member of the immunotherapy working group and contributes to research and guidelines. He is the Principle Investigator for the Myeloma UK funded NIHR Myeloma Health Informatics Collaborative.

Specialties

Research interests

He is the chief investigator on many myeloma clinical trials and is particularly involved in the development of novel treatments, including antibody drug conjugates, bispecific antibodies and CAR-T cell therapy.

Publications

  • International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma. Costa LJ, Banerjee R, Mian H, Weisel K, Bal S, Derman BA, Htut MM, Nagarajan C, Rodriguez C, Richter J, Frigault MJ, Ye JC, van de Donk NWCJ, Voorhees PM, Puliafito B, Bahlis N, Popat R, Chng WJ, Ho PJ, Kaur G, Kapoor P, Du J, Schjesvold F, Berdeja J, Einsele H, Cohen AD, Mikhael J, Biru Y, Rajkumar SV, Lin Y, Martin TG, Chari A. Leukemia. 2025 Jan 27
  • The UK consensus supporting effective introduction of novel treatments for multiple myeloma in the National Health Service. Popat R, Basu S, Henshaw S, Karunanithi K, Ramasamy K, Singh I, Tailor A, Walker I, Warren T, Ali N, Duffield C, Cook G. EJHaem. 2024 Oct 25;5(6):1133-1143
  • Results from Arm A of Phase 1/2 DREAMM-6 trial: belantamab mafodotin with lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma. Popat R, Augustson B, Gironella M, Lee C, Cannell P, Patel N, Kasinathan RS, Rogers R, Shaikh M, Curry A, Carreño F, Roy-Ghanta S, Opalinska J, Quach H.Blood Cancer J. 2024 Oct 21;14(1):184.
  • International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma.Rodriguez-Otero P, Usmani S, Cohen AD, van de Donk NWCJ, Leleu X, Gállego Pérez-Larraya J, Manier S, Nooka AK, Mateos MV, Einsele H, Minnema M, Cavo M, Derman BA, Puig N, Gay F, Ho PJ, Chng WJ, Kastritis E, Gahrton G, Weisel K, Nagarajan C, Schjesvold F, Mikhael J, Costa L, Raje NS, Zamagni E, Hájek R, Weinhold N, Yong K, Ye JC, Sidhana S, Merlini G, Martin T, Lin Y, Chari A, Popat R, Kaufman JL; International Myeloma Working Group. Lancet Oncol. 2024 May;25(5):e205-e216
  • Daratumumab combinations for patients with newly diagnosed and relapsed multiple myeloma. Popat R, Chavda SJ. Lancet Haematol. 2023 Oct;10(10):e788-e789
  • Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma.Richardson PG, Trudel S, Popat R, Mateos MV, Vangsted AJ, Ramasamy K, Martinez-Lopez J, Quach H, Orlowski RZ, Arnao M, Lonial S, Karanes C, Pawlyn C, Kim K, Oriol A, Berdeja JG, Rodríguez Otero P, Casas-Avilés I, Spirli A, Poon J, Li S, Gong J, Wong L, Lamba M, Pierce DW, Amatangelo M, Peluso T, Maciag P, Katz J, Pourdehnad M, Bahlis NJ; CC-92480-MM-001 Study Investigators.N Engl J Med. 2023 Sep 14;389(11):1009-1022.
  • Limited efficacy of APRIL CAR in patients with multiple myeloma indicate challenges in the use of natural ligands for CAR T-cell therapy. Lee L, Lim WC, Galas-Filipowicz D, Fung K, Taylor J, Patel D, Akbar Z, Alvarez Mediavilla E, Wawrzyniecka P, Shome D, Reijmers RM, Gregg T, Wood L, Day W, Cerec V, Ferrari M, Thomas S, Cordoba S, Onuoha S, Khokhar N, Peddareddigari V, Al-Hajj M, Cavet J, Zweegman S, Rodriguez-Justo M, Youg K, Pule M, Popat R. J Immunother Cancer. 2023 Jun;11(6):
  • Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.San-Miguel J, Dhakal B, Yong K, Spencer A, Anguille S, Mateos MV, Fernández de Larrea C, Martínez-López J, Moreau P, Touzeau C, Leleu X, Avivi I, Cavo M, Ishida T, Kim SJ, Roeloffzen W, van de Donk NWCJ, Dytfeld D, Sidana S, Costa LJ, Oriol A, Popat R, Khan AM, Cohen YC, Ho PJ, Griffin J, Lendvai N, Lonardi C, Slaughter A, Schecter JM, Jackson CC, Connors K, Li K, Zudaire E, Chen D, Gilbert J, Yeh TM, Nagle S, Florendo E, Pacaud L, Patel N, Harrison SJ, Einsele H. N Engl J Med. 2023 Jul 27;389(4):335-347
  • Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib-cyclophosphamide-dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON): a randomised, phase 2, non-inferiority trial. Yong K, Wilson W, de Tute RM, Camilleri M, Ramasamy K, Streetly M, Sive J, Bygrave CA, Benjamin R, Chapman M, Chavda SJ, Phillips EH, Del Mar Cuadrado M, Pang G, Jenner R, Dadaga T, Kamora S, Cavenagh J, Clifton-Hadley L, Owen RG, Popat R. Lancet Haematol. 2023 Feb;10(2):e93-e10